Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 7/20 | 0.35 |
| ▸ | CA2 | P00918 | 6/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.35 |
| ▸ | CA1 | P00915 | 6/20 | 0.35 |
| ▸ | CA9 | Q16790 | 4/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1927057 | 0.95 | CA2 (0.35) | CA12CA2CA14CA1CA9 | |
| SCHEMBL13270349 | 0.84 | CA12 (0.36) | CA12CA2CA14CA1CA9 | |
| SCHEMBL13270350 | 0.84 | TDP1 (0.42) | CA12CA2CA14CA1CA9 | |
| SCHEMBL1927059 | 0.82 | CA12 (0.35) | CA12CA2CA14CA1CA9 | |
| SCHEMBL19931568 | 0.80 | ALDH1A1 (0.44) | CA12CA2CA14CA1CA9 | |
| SCHEMBL1925644 | 0.80 | CA1 (0.42) | CA12CA2CA1CA9TDP1 | |
| SCHEMBL1925646 | 0.80 | TDP1 (0.50) | CA12CA2CA1CA9TDP1 | |
| SCHEMBL1928334 | 0.80 | HTT (0.32) | CA12CA2CA1CA9TDP1 | |
| SCHEMBL1927273 | 0.79 | DGAT1 (0.41) | CA12CA2CA14CA1CA9 | |
| SCHEMBL29422137 | 0.79 | CA12 (0.41) | CA12CA2CA14CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105919987-B | N-acyloxysulfonamide and N-hydroxy-N-acylsulfonamide derivatives and uses thereof | 约翰斯霍普金斯大学 | 2020-04-03 | — | — | CN | disclosed |
| EP-2509941-B1 | N-ACYLATED HYDROXYLAMINE DERIVATIVES AND O-ACYLATED HYDROXYLAMINE DERIVATIVES | UNIV JOHNS HOPKINS (US) | 2019-01-23 | — | — | EP | disclosed |
| US-20180050985-A1 | N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES | THE JOHNS HOPKINS UNIVERSITY | 2018-02-22 | — | — | US | disclosed |
| US-9458127-B2 | Bis-acylated hydroxylamine derivatives | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160046570-A1 | N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES | THE JOHNS HOPKINS UNIVERSITY | 2016-02-18 | — | — | US | disclosed |
| US-20150197502-A1 | Bis-Acylated Hydroxylamine Derivatives | THE JOHNS HOPKINS UNIVERSITY | 2015-07-16 | — | — | US | disclosed |
| US-9018411-B2 | Bis-acylated hydroxylamine derivatives | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20140235636-A1 | N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20110144067-A1 | N-Acyloxysulfonamide and N-Hydroxy-N-Acylsulfonamide Derivatives | THE JOHNS HOPKINS UNIVERSITY | 2011-06-16 | — | — | US | disclosed |
| US-20110136827-A1 | Bis-Acylated Hydroxylamine Derivatives | THE JOHNS HOPKINS UNIVERSITY | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235636-A1 | N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES | TNNI3, TNNT2, TNNC1 | CA12 1675/4885CA2 425/4885CA14 1887/4885 |
| US-20150197502-A1 | Bis-Acylated Hydroxylamine Derivatives | CPT1A, TNNI3, NOS2 | CA12 1963/4885CA2 627/4885CA14 2370/4885 |
| US-20180050985-A1 | N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES | TNNI3, TNNT2, NOS2 | CA12 1707/4885CA2 418/4885CA14 1889/4885 |
| US-20160046570-A1 | N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES | TNNI3, TNNT2, TNNC1 | CA12 1675/4885CA2 425/4885CA14 1887/4885 |
| US-20110144067-A1 | N-Acyloxysulfonamide and N-Hydroxy-N-Acylsulfonamide Derivatives | TNNI3, TNNT2, TNNC1 | CA12 1675/4885CA2 425/4885CA14 1887/4885 |
| US-20110136827-A1 | Bis-Acylated Hydroxylamine Derivatives | CPT1A, TNNI3, NOS2 | CA12 1963/4885CA2 627/4885CA14 2370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.